ArticleCHEST pulmonary2026
Nontuberculous Mycobacteria Pulmonary Disease Prevalence, New York City, 2012 to 2020.
Article in CHEST pulmonary, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Background: Nontuberculous mycobacteria pulmonary disease (NTM PD) has been increasing in the United States, and New York City is an important hotspot, with a high burden of disease. Research Question: We assessed how neighborhood-level risk factors influenced NTM PD prevalence in New York City. Study Design and Methods: We used outpatient claims data from hospitals participating in the Patient-Centered Outcomes Research Institute network, compiled by the INSIGHT Clinical Research Network at Weill Cornell Medicine. NTM PD period prevalence (referred to here as 'prevalence') was estimated by New York City neighborhood for the study period 2012 through 2022. A case was defined as someone with at least one claim for NTM PD. De-identified NTM PD case data and demographic data were analyzed by neighborhood of residence at diagnosis. Using prevalence estimates, we detected high- and low-prevalence regions within New York City and associated these estimates with demographic, clinical, socioeconomic, and environmental neighborhood-level factors using Poisson regression and backward elimination of covariates. Results: Overall, 6,169 NTM PD cases were identified among persons receiving care across 17 private New York City hospitals. The mean age was 67.5 years, 68.7% were female, and 57.3% were White. Over the study period, NTM PD prevalence increased throughout New York City, and median year built of housing units, median income, and median age of residents were significant neighborhood-level risk factors. The highest prevalence neighborhoods were in Manhattan, while the lowest prevalence neighborhoods were in Brooklyn and Staten Island. Interpretation: Our findings indicate that neighborhood-level access to care may explain the heterogeneity in NTM PD prevalence among New York City neighborhoods, as higher income, newer neighborhoods exhibited the highest NTM PD prevalences. Future studies should examine the extent of undetected NTM PD in New York City, particularly in low-income areas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.